BMRA (Biomerica) Selling, General, & Admin. Expense: $4.71 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRA Biomerica Inc BMRA
54 GF Score
Price $1.60
GF Value $2.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Biomerica Selling, General, & Admin. Expense?

Biomerica BMRA -1.23% 54 Selling, General, & Admin. Expense is $4.71 Mil as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 54/100 and a GF Value™ of $2.18 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Biomerica's selling, general, & admin. expense for the three months ended in Feb. 2026 was $1.08 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Feb. 2026 was $4.71 Mil.


Biomerica  (NAS:BMRA) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Biomerica Selling, General, & Admin. Expense Related Terms


Biomerica Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Biomerica's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica Selling, General, & Admin. Expense Chart

Biomerica Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.67 5.70 6.09 5.49 4.61

Biomerica Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 1.07 1.33 1.23 1.08

BMRA vs WOK, ALURD, ITOC: Selling, General, & Admin. Expense Comparison

For the Medical Devices subindustry, Biomerica's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Biomerica's Selling, General, & Admin. Expense falls into.


BMRA
54GF Score
Biomerica Inc BMRA
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomerica Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $4.71 Mil mean?
Biomerica (BMRA) has a Selling, General, & Admin. Expense of $4.71 Mil as of Feb. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Biomerica and its competitors.
Is Biomerica's Selling, General, & Admin. Expense too high?
Biomerica's current Selling, General, & Admin. Expense is $4.71 Mil. Overall, Biomerica has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Selling, General, & Admin. Expense compare to WOK and ALURD?
Biomerica's Selling, General, & Admin. Expense of $4.71 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Biomerica and its competitors. Biomerica's current Selling, General, & Admin. Expense is $4.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.18, compared to a current price of $1.60 — trading 26.6% below its estimated fair value. The current Selling, General, & Admin. Expense is $4.71 Mil. Biomerica's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Biomerica (BMRA), the current Selling, General, & Admin. Expense is $4.71 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomerica (BMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Biomerica stock appears to be undervalued. The current stock price of $1.60 is trading 26.6% below its estimated GF Value™ of $2.18. GuruFocus considers Biomerica to be Modestly Undervalued.

Key valuation signals for BMRA:

  • Selling, General, & Admin. Expense: $4.71 Mil
  • GF Value™: $2.18 vs. price of $1.60 (26.6% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biomerica Business Description

Address 17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
54GF Score

Get the complete analysis for BMRA

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$2.18
GF Value